Robert Metz
Director/Board Member at Cures Within Reach
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Aaron Cox | M | 41 | 8 years | |
| Vikram Karnani | M | 49 | 10 years | |
| Patrick McIlvenny | M | 45 | 9 years | |
| Barbara Goodman | F | - |
Cures Within Reach
| 7 years |
| Lucy Mancini-Newell | F | - |
Cures Within Reach
| - |
| Matthew Rich | M | - |
Cures Within Reach
| - |
| Nancy Sullivan | F | - |
Cures Within Reach
| - |
| Michael DesJardin | M | 66 | 8 years | |
| Geoffrey M. Curtis | M | 49 | 9 years | |
| Irina P. Konstantinovsky | F | 54 | 7 years | |
| Margaret Christie | F | - |
Cures Within Reach
| - |
| Kristina Allikmets | M | - |
Cures Within Reach
| - |
| Steve Braun | M | - |
Cures Within Reach
| - |
| Nick Manusos | M | - |
Cures Within Reach
| - |
| David Styler | M | - |
Cures Within Reach
| - |
| Keli Walbert | F | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Barry L. Golombik | M | - |
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Marilyn Vetter | F | - | - | |
| Barry Moze | M | 70 | 8 years | |
| Robert J. de Vaere | M | 66 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | 6 years |
| Mary Martin | M | - | 1 years | |
| William Daniel | M | 72 | 9 years | |
| Brian Beeler | M | 51 | 9 years | |
| Gino Santini | M | 66 | 11 years | |
| Paul Hoelscher | M | 59 | 8 years | |
| Virinder Nohria | M | 70 | 3 years | |
| George Tidmarsh | M | 64 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | 5 years |
| James Shannon | M | 67 | 6 years | |
| Michael Grey | M | 71 | 12 years | |
| Susan Mahony | M | 59 | 4 years | |
| Pascale Witz | F | 57 | 6 years | |
| H. Watkins | M | 71 | 9 years | |
| Ronald E. Pauli | M | 63 | 8 years | |
| Eric B. Mosbrooker | M | 46 | 2 years | |
| Richard Federer | M | - | - | |
| John J. Kody | M | - | 2 years | |
| Sherri Stewart | F | - | 3 years | |
| Jeffrey Kent | M | 62 | - | |
| Michael Conick Hanley | M | 51 | 2 years | |
| Tim Ayers | M | - | 3 years | |
| George Hampton | M | 54 | - | |
| Javier Szwarcberg | M | 54 | 1 years | |
| Tina Ventura | F | - | - | |
| Shao Lee Lin | M | 57 | 2 years | |
| Elizabeth Thompson | M | 49 | - | |
| Daniel Camardo | M | 55 | 7 years | |
| Amy Grahn | F | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| David Happel | M | 62 | 2 years | |
| Steven Pfeiffer | M | 48 | 1 years | |
| Iain W. Duncan | M | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Timothy Walbert | M | 57 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Todd Smith | M | 55 | - | |
| Jeff Bird | M | 63 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Louis C. Bock | M | 59 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Patrick Enright | M | 62 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Patrick Ashe | M | 59 | - | |
| John Devane | M | - | - | |
| Robert Carey | M | 65 | 5 years | |
| Keith S. Swenson | M | - | - | |
| Miles W. McHugh | M | 59 | 8 years | |
| John B. Thomas | M | - | 2 years | |
| Carolyn Feamster | F | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Mike Li | M | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| David George Kelly | M | 63 | 4 years | |
| Michael Kelliher | M | 47 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Ireland | 46 | 70.77% |
| United States | 20 | 30.77% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert Metz
- Personal Network